Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 12, 2015, Pages 2166-2172

  Muir, Andrew J ^a,b   Naggie, Susanna ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiviral Agents; Diagnosis; Disease Management; Hepatitis C

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; GRAZOPREVIR; GS 5815; GS 9857; HEPACIVIRIN INHIBITOR; LEDIPASVIR; NONSTRUCTURAL PROTEIN 5A INHIBITOR; SOFOSBUVIR; UNCLASSIFIED DRUG;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CHRONIC KIDNEY DISEASE; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HEALTH PROGRAM; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; LIVER TRANSPLANTATION; MIXED INFECTION; REVIEW; SCREENING TEST; CLASSIFICATION; DRUG THERAPY; ECONOMICS; GENETICS; GENOTYPE; HEALTH; HEPACIVIRUS; HEPATITIS C, CHRONIC; PROCEDURES; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; DRUG THERAPY; GENOTYPE; GLOBAL HEALTH; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; TREATMENT OUTCOME;

EID: 84944390503     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.07.015     Document Type: Review

References (44)

1. Lawitz E., Mangia A., Wyles D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013, 368:1878-1887.
2. Sulkowski M.S., Gardiner D.F., Rodriguez-Torres M., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014, 370:211-221.
3. Poordad F., Hezode C., Trinh R., et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014, 370:1973-1982.
4. Kwo P.Y., Mantry P.S., Coakley E., et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014, 371:2375-2382.
5. Charlton M., Everson G.T., Flamm S.L., et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015, 149:649-659.
6. Sulkowski M.S., Naggie S., Lalezari J., et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014, 312:353-361.
7. Sulkowski M.S., Eron J.J., Wyles D., et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 2015, 313:1223-1231.
8. Recommendations for testing, managing, and treating hepatitis C. 2015. Available at:. Accessed June 1, 2015. http://hcvguidelines.org/.
9. Zeuzem S., Dusheiko G.M., Salupere R., et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014, 370:1993-2001.
10. Svarovskaia E.S., Dvory-Sobol H., Parkin N., et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis 2014, 59:1666-1674.
11. Wyles D., Pockros P., Morelli G., et al. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology 2015, 61:1793-1797.
12. McCormick A.L., Moynihan L., Macartney M.J., et al. Baseline drug resistance mutations are detectable in HCV genes NS3 and NS5A but not NS5B in acute and chronic HIV-coinfected patients. Antivir Ther 2015, 20:361-363.
13. Sarrazin C, Dvory-Sobol H, Svarovskaia E. Baseline and post-baseline resistance analyses of phase 2/3 studies of ledipasvir/sofosbuvir ± RBV. American Association for the Study of Liver Diseases (AASLD) Liver Meeting, Boston, MA, 2014:abstract 1926.
14. Nelson D.R., Cooper J.N., Lalezari J.P., et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015, 61:1127-1135.
15. Wang C., Jia L., O'Boyle D.R., et al. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity. Antimicrob Agents Chemother 2014, 58:5155-5163.
16. Tran TT, Morgan TR, Thuvulath PJ. Safety and efficacy of treatment with sofosbuvir+GS-5816+/-ribavirin for 8 or 12 weeks in treatment naive patients with genotype 1-6 HCV infection. American Association for the Study of Liver Diseases (AASLD) Liver Meeting, November 7-12, 2014, Boston, MA: abstract 80.
17. Zeuzem S., Ghalib R., Reddy K.R., et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015, 163:1-13.
18. Chhatwal J., Kanwal F., Roberts M.S., et al. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 2015, 162:397-406.
19. Kamal-Yanni M. Hepatitis C drug affordability. Lancet Glob Health 2015, 3:e73-e74.
20. Holmberg S.D., Spradling P.R., Moorman A.C., et al. Hepatitis C in the United States. N Engl J Med 2013, 368:1859-1861.
21. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998, 47(RR-19):1-39. Centers for Disease Control and Prevention.
22. Smith B.D., Morgan R.L., Beckett G.A., et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012, 61(RR-4):1-32.
23. Ferrante J.M., Winston D.G., Chen P.H., et al. Family physicians' knowledge and screening of chronic hepatitis and liver cancer. Fam Med 2008, 40:345-351.
24. Frazer K., Glacken M., Coughlan B., et al. Hepatitis C virus infection in primary care: survey of registered nurses' knowledge and access to information. J Adv Nurs 2011, 67:327-339.
25. Agrawal A., Mayo-Smith M.F. Adherence to computerized clinical reminders in a large healthcare delivery network. Stud Health Technol Inform 2004, 107(Pt 1):111-114.
26. Armstrong G.L., Wasley A., Simard E.P., et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144:705-714.
27. Weinbaum C., Lyerla R., Margolis H.S., et al. Prevention and control of infections with hepatitis viruses in correctional settings: Centers for Disease Control and Prevention. MMWR Recomm Rep 2003, 52(RR-1):1-36. quiz CE1-CE4.
28. Galbraith J.W., Franco R.A., Donnelly J.P., et al. Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department. Hepatology 2015, 61:776-782.
29. Delarocque-Astagneau E., Meffre C., Dubois F., et al. The impact of the prevention programme of hepatitis C over more than a decade: the French experience. J Viral Hepat 2010, 17:435-443.
30. Scalioni Lde P., Cruz H.M., de Paula V.S., et al. Performance of rapid hepatitis C virus antibody assays among high- and low-risk populations. J Clin Virol 2014, 60:200-205.
31. McGowan C.E., Fried M.W. Barriers to hepatitis C treatment. Liver Int 2012, 32(Suppl 1):151-156.
32. Trooskin S.B., Poceta J., Towey C.M., et al. Results from a geographically focused, community-based HCV screening, linkage-to-care and patient navigation program. J Gen Intern Med 2015, 30:950-957.
33. Masson C.L., Delucchi K.L., McKnight C., et al. A randomized trial of a hepatitis care coordination model in methadone maintenance treatment. Am J Public Health 2013, 103:e81-e88.
34. Arora S., Thornton K., Murata G., et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011, 364:2199-2207.
35. Knobler S, Lederberg J, Pray LA, eds. Considerations for viral disease eradication: lessons learned and future strategies-workshop summary. National Academies Press, Washington, DC, 2002.
36. CDC. Reported cases of acute, hepatitis C, by state: United States, 2007-2011. Available at:. Accessed April 10, 2014. http://www.cdc.gov/hepatitis/Statistics/2011Surveillance/Table4.1.htm.
37. Hepatitis C virus infection among adolescents and young adults: Massachusetts, 2002-2009. MMWR Morb Mortal Wkly Rep 2011, 60:537-541.
38. Notes from the field: hepatitis C virus infections among young adults-rural Wisconsin, 2010. MMWR Morb Mortal Wkly Rep 2012, 61:358.
39. Strickland G.T. Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. Hepatology 2006, 43:915-922.
40. Hauri A.M., Armstrong G.L., Hutin Y.J. The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS 2004, 15:7-16.
41. Apata I.W., Averhoff F., Pitman J., et al. Progress toward prevention of transfusion-transmitted hepatitis B and hepatitis C infection: sub-Saharan Africa, 2000-2011. MMWR Morb Mortal Wkly Rep 2014, 63:613-619.
42. Mohamoud Y.A., Mumtaz G.R., Riome S., et al. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis 2013, 13:288.
43. Guidelines for the screening, care and treatment of persons with hepatitis C infection 2014, WHO, WHO Press, Geneva.
44. Chen T.Y., Ding E.L., Seage Iii G.R., et al. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 2009, 49:1605-1615.